CN107847597A - 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂 - Google Patents

包含与抗体组合施予的ido抑制剂的肿瘤治疗剂 Download PDF

Info

Publication number
CN107847597A
CN107847597A CN201680041307.3A CN201680041307A CN107847597A CN 107847597 A CN107847597 A CN 107847597A CN 201680041307 A CN201680041307 A CN 201680041307A CN 107847597 A CN107847597 A CN 107847597A
Authority
CN
China
Prior art keywords
antibody
amino acid
acid sequence
cdr
people
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680041307.3A
Other languages
English (en)
Chinese (zh)
Inventor
德永昌浩
石井俊彦
三重元弥
安藤宗稔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of CN107847597A publication Critical patent/CN107847597A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201680041307.3A 2015-07-14 2016-07-14 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂 Pending CN107847597A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562192173P 2015-07-14 2015-07-14
US62/192,173 2015-07-14
PCT/JP2016/003337 WO2017010106A1 (en) 2015-07-14 2016-07-14 A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody

Publications (1)

Publication Number Publication Date
CN107847597A true CN107847597A (zh) 2018-03-27

Family

ID=57757291

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680041307.3A Pending CN107847597A (zh) 2015-07-14 2016-07-14 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂

Country Status (10)

Country Link
US (2) US20180271861A1 (https=)
EP (2) EP3991749A3 (https=)
JP (2) JP2018524361A (https=)
KR (1) KR102823683B1 (https=)
CN (1) CN107847597A (https=)
AU (1) AU2016293667A1 (https=)
CA (1) CA2992238A1 (https=)
HK (1) HK1252514A1 (https=)
TW (1) TW201713332A (https=)
WO (1) WO2017010106A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112601526A (zh) * 2018-08-29 2021-04-02 凯莫森特里克斯股份有限公司 使用c-c趋化因子受体4(ccr4)拮抗剂和一种或多种检查点抑制剂的联合治疗

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3070295A1 (en) 2017-07-28 2019-01-31 Phanes Therapeutics, Inc. Anti-tim-3 antibodies and uses thereof
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
CN112961239B (zh) * 2021-02-24 2021-09-10 北京昭衍生物技术有限公司 Tim抑制剂及其应用
WO2022184930A2 (en) 2021-03-05 2022-09-09 Universität Basel Compositions for the treatment of ebv associated diseases or conditions
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677A (en) 1848-07-25 Improvement in hillside-plows
US171A (en) 1837-04-20 Machine for washing iron and other ores
US5821A (en) 1848-10-03 Cream-freezer
US4968A (en) 1847-02-13 Spinal elevator
US337A (en) 1837-07-31 Mode of constructing railroad-frogs
US603A (en) 1838-02-15 Improvement in the construction of many-chambered fire-arms
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
WO1999029310A2 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
CN100455599C (zh) 2000-03-03 2009-01-28 协和发酵工业株式会社 基因重组抗体及其抗体片段
PT1449850E (pt) 2001-08-31 2011-02-02 Kyowa Hakko Kirin Co Ltd Anticorpos humanos enxertados em rdc¿s e fragmentos desses anticorpos
AU2003303082B2 (en) 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
WO2005057341A2 (en) 2003-12-02 2005-06-23 Koolspan, Inc. Automatic hardware-enabled virtual private network system
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
CA2682382A1 (en) * 2007-03-28 2008-10-09 Biogen Idec Inc. Non-fucosylated antibodies
CA2965198C (en) 2008-01-15 2021-02-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
PL2315756T3 (pl) * 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
WO2010053182A1 (ja) 2008-11-10 2010-05-14 協和発酵キリン株式会社 キヌレニン産生抑制剤
US8492119B2 (en) * 2009-04-27 2013-07-23 Kyowa Hakko Kirin Co., Ltd Antibody to human IL-3 receptor alpha chain
CA2773579C (en) 2009-09-10 2019-01-15 Kyowa Kirin Co., Ltd. Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
WO2011042065A1 (en) 2009-10-09 2011-04-14 Daniel Monsch "momoheli" lifting module and vehicles
TWI535442B (zh) * 2010-05-10 2016-06-01 Kyowa Hakko Kirin Co Ltd A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
WO2011155607A1 (ja) * 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
JP6047497B2 (ja) 2011-11-09 2016-12-21 協和発酵キリン株式会社 含窒素複素環化合物
JP6224619B2 (ja) * 2012-12-07 2017-11-01 協和発酵キリン株式会社 抗ｆｏｌｒ１抗体
CN105209449B (zh) * 2013-03-14 2019-02-01 库拉德夫制药私人有限公司 犬尿氨酸途径的抑制剂
EA029126B1 (ru) 2013-07-01 2018-02-28 Бристол-Майерс Сквибб Компани Ингибиторы ido
DK3066085T3 (da) * 2013-11-08 2020-06-02 Incyte Holdings Corp Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor
EP3153178A4 (en) 2014-06-06 2017-12-20 Kyowa Hakko Kirin Co., Ltd. Method for treating cancer patients using folr1 targeted drug and antifolate, and drug

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HENRI-ALEXANDRE MICHAUD等: ""Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity"", 《ONCOIMMUNOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112601526A (zh) * 2018-08-29 2021-04-02 凯莫森特里克斯股份有限公司 使用c-c趋化因子受体4(ccr4)拮抗剂和一种或多种检查点抑制剂的联合治疗

Also Published As

Publication number Publication date
JP2021191780A (ja) 2021-12-16
JP2018524361A (ja) 2018-08-30
EP3991749A3 (en) 2022-08-24
JP7366093B2 (ja) 2023-10-20
EP3991749A2 (en) 2022-05-04
HK1252514A1 (zh) 2019-05-31
EP3322444A1 (en) 2018-05-23
KR102823683B1 (ko) 2025-06-23
US20220088011A1 (en) 2022-03-24
KR20180025897A (ko) 2018-03-09
EP3322444A4 (en) 2019-06-12
CA2992238A1 (en) 2017-01-19
TW201713332A (zh) 2017-04-16
WO2017010106A1 (en) 2017-01-19
AU2016293667A1 (en) 2018-01-04
US20180271861A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
JP7366093B2 (ja) 抗体と併用投与されるｉｄｏ阻害剤含有腫瘍治療剤
ES2850428T3 (es) Procedimientos de monitorización y tratamiento del cáncer
Roth et al. Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies
US20210401979A1 (en) Dosing Parameters for CD47 Targeting Therapies to Hematologic Malignancies
Correale et al. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC)
CN107810011A (zh) 使用抗ox40抗体治疗癌症的方法
Sun et al. Epidermal growth factor receptor expression in acute myelogenous leukaemia is associated with clinical prognosis
JP2017503001A (ja) がんを処置するための療法
HK1251474A1 (zh) 使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
JP2016537433A (ja) 骨髄増殖性障害を処置するための治療
RS61152B2 (sr) Terapeutski i dijagnostički postupci za lečenje raka
RS59738B1 (sr) Anti-ox40 antitela i postupci primene
CN105339009A (zh) 用于治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法
Eglenen-Polat et al. A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer
JP2020517629A5 (https=)
CN113196061A (zh) 肉瘤样肾癌的诊断和治疗方法
Mancuso et al. Novel systemic therapy against malignant pleural mesothelioma
Zandberg et al. Window studies in squamous cell carcinoma of the head and neck: values and limits
Lu et al. Combined treatment with cetuximab and STA9090 has synergistic anticancer effects on human non-small cell lung cancer: Combined treatment with cetuximab and STA9090 in NSCLC
TW202416995A (zh) 用於治療與至少一種抗體分泌細胞標記物之表現相關的疾病的腺苷受體拮抗劑及其組合物
Recasens Zorzo Preclinical evaluation of the antitumor activity of a new CXCR4 inhibitor: a novel therapeutic approach in diffuse large B-cell lymphoma
WO2022271955A1 (en) Novel targeted shrna nanoparticles for cancer therapy
Schlafstein et al. Therapeutic Target
NISHIBATA Studies on Molecular Targeted Agents as Candidates of Combination Partner for Cancer Immunotherapy
EA050897B1 (ru) Способ лечения пациентов с пониженной чувствительностью к ингибитору bcl-2

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Tokyo, Japan

Applicant after: KYOWA HAKKO KIRIN Co.,Ltd.

Address before: Tokyo, Japan

Applicant before: Kyowa Hakko Kirin Co.,Ltd.

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20180327

RJ01 Rejection of invention patent application after publication